NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis $1.04 -0.05 (-4.59%) Closing price 04:00 PM EasternExtended Trading$1.04 0.00 (0.00%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About InflaRx Stock (NASDAQ:IFRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InflaRx alerts:Sign Up Key Stats Today's Range$1.03▼$1.1250-Day Range$1.09▼$2.1252-Week Range$0.80▼$2.95Volume472,107 shsAverage Volume1.07 million shsMarket Capitalization$153.26 millionP/E RatioN/ADividend YieldN/APrice Target$7.43Consensus RatingModerate Buy Company Overview InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions. Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More InflaRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreIFRX MarketRank™: 2.45752260893 of 5 starsInflaRx scored higher than 49% of companies evaluated by MarketBeat, and ranked 492nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingInflaRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInflaRx has a consensus price target of $7.43, representing about 610.9% upside from its current price of $1.05.Amount of Analyst CoverageInflaRx has only been the subject of 3 research reports in the past 90 days.Read more about InflaRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for InflaRx are expected to decrease in the coming year, from ($0.22) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.41% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 15.02, which indicates bearish sentiment.Change versus previous monthShort interest in InflaRx has recently increased by 0.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentInflaRx has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.Search Interest3 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows4 people have added InflaRx to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InflaRx's insider trading history. Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IFRX Stock News HeadlinesHere's why InflaRx (IFRX) is a great buy the bottom stock nowNovember 13, 2026 | msn.comInflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock UpNovember 9, 2026 | rttnews.comA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.November 20 at 1:00 AM | Monetary Gold (Ad)InflaRx (IFRX) AI Stock AnalysisNovember 7, 2026 | tipranks.comInflaRx Highlights Positive Phase 1 Findings For Oral Drug Candidate Izicopan; Stock DownNovember 6, 2026 | rttnews.comInflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanNovember 6, 2026 | globenewswire.comInflaRx NV Presents Clinical Development Strategy And Commercial Vision For Izicopan In ANCA-Associated VasculitisNovember 4, 2026 | marketscreener.comMInflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Headlines IFRX Stock Analysis - Frequently Asked Questions How have IFRX shares performed this year? InflaRx's stock was trading at $1.01 on January 1st, 2026. Since then, IFRX stock has increased by 3.5% and is now trading at $1.0450. How were InflaRx's earnings last quarter? InflaRx N.V. (NASDAQ:IFRX) announced its earnings results on Tuesday, November, 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.04. When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,667,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are InflaRx's major shareholders? Top institutional investors of InflaRx include Nantahala Capital Management LLC (1.83%), Marshall Wace LLP (0.68%), Jefferies Financial Group Inc. (0.49%) and T3 Companies LLC (0.30%). How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include ADMA Biologics (ADMA), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Novavax (NVAX) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/03/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, IFRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IFRX CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees65Year Founded2006Price Target and Rating Average Price Target for InflaRx$7.43 High Price Target$14.00 Low Price Target$2.00 Potential Upside/Downside+610.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.63 million Net MarginsN/A Pretax Margin-149,706.05% Return on Equity-32.04% Return on Assets-27.33% Debt Debt-to-Equity RatioN/A Current Ratio7.26 Quick Ratio7.26 Sales & Book Value Annual Sales$30 thousand Price / Sales5,133.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book0.92Miscellaneous Outstanding Shares147,370,000Free Float123,347,000Market Cap$154.00 million OptionableOptionable Beta2.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IFRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.